ACREDITACION | DAVIDSON MESTMAN

ACCREDITATION

DISCLOSURE OF INTERESTS

All conflicts of interest of any individual in a position to manage the content of this CME activity will be identified and mitigated before this educational activity is provided. Publication of relationships between vendors and speakers, or lack thereof, will be provided to attendees.

FACULTY

COMPANY/S (TYPE OF RELATIONSHIP)

Jaime A. Davidson, MD

Does not have

Eduardo Sánchez, MD

Does not have

Violet Lagari, MD

Does not have

Andrew Blakely, MD

Does not have

Mark Jara, MD

Does not have

Jaydira Del Rivero, MD

Does not have

Laura Boucai, MD

Does not have

Carolina Masri, MD

Does not have

Ingrid Libman, MD

Does not have

Ricardo Correa, M.D

Does not have

Carolina Solis-Herrera, MD

Speaker and Advisor Novo Nordisk and Bayer

Maria Delgado Lelievre, MD

Ineligible Companies: Medtronic, Biobeat Advisory Board: Medtronic, Biobeat Benefits Received (Financial or Otherwise): Advisory Board: Medtronic, Biobeat

Mauricio Cohen, MD

Abbott Medical, Consultant, Honoraria (< $5000) Cordis, Consultant, Honoraria (< $5000) Accumed Radial Systems, Ownership

Guillermo Umpierrez, MD

The name of the ineligible company(ies): Grant support: Dexcom, Abbott, Bayer, Ad Board: Dexcom, GlyCare. Any benefits received: (financial or otherwise): Ad Board: Dexcom and GlyCare

Antonio Bianco, MD

Consultant: AbbVie, Acella, Synthonics, Aligos

Francisco Pasquel, MD

The name of the ineligible companies with which you have a relationship: Dexcom, Insulet, Ideal Medical Technologies, Novo Nordisk, Tandem Diabetes Care.
Your role/relationship with the company: Research: Dexcom, Insulet, Ideal Medical Technologies, Novo Nordisk, Tandem Diabetes Care, Consulting: Dexcom, Insulet.
Any benefits received (financial or otherwise): Devices for Research: Dexcom and Insulet, Dexcom: personal fees for consulting, Insulet: fees to Emory University

Rodolfo Galindo, M.D

RJG is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) under award numbers P30DK111024, 1K23DK123384, and 1R03DK138255. RJG received research support from Novo Nordisk, Eli Lilly, Boehringer, and Dexcom, and consulting/advisory from Abbott Diabetes, Bayer, Dexcom, Eli Lilly, and Novo Nordisk, and Medtronic.

PROGRAM ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint organization of the University of Miami Leonard M. Miller School of Medicine and Conviction2, Inc The University of Miami Leonard M. Miller School of Medicine is accredited by ACCME to provide continuing education for physicians.

CERTIFICATE DESIGNATION

The University of Miami Leonard M. Miller School of Medicine assigns this live activity a maximum of 24.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST MITIGATION

All conflicts of interest of any individual in a position to control the content of this Continuing Medical Education (CME) activity will be identified and mitigated prior to this educational activity being provided. Information about provider and faculty relationships, or the lack thereof, will be disclosed to participants.

LEARNING OBJECTIVES

Develop the most appropriate management strategies for endocrine patients according to the latest developments and treatment advances.

Determine the optimal management of different endocrine diseases such as Graves' orbitopathy, Cushing's syndrome, thyroid cancer, non-classical adrenal hyperplasia, acromegaly and polycystic ovary syndrome.

Modulate treatments for endocrine diseases based on the latest discoveries on the genetic basis and the pathogenic mechanisms involved.

Evaluate the latest findings from studies on cardiovascular risk, hypoglycemia, and kidney disease in order to provide the best possible therapeutic approach to those subpopulations at highest risk.

To evaluate the performance of the drugs SGLT-2s and GLP1-RAs as well as the implementation of new personalized strategies in order to improve results in the endocrine patient.

Develop ad-hoc treatment strategies for diabetic patients using the latest technologies available in the field.

Apply the evidence-based recommendations of the consensus clinical guidelines to inform the choice of the most suitable therapy, its follow-up and support strategies for overweight and obese patients.

Describe the lack of representation of minorities in clinical trials as well as define possible solutions to this problem.

Evaluate existing opportunities to improve access to treatments for minorities.

OBTAINING CME CREDITS

After the program, the University of Miami will send you an assessment that you must complete online and then you will receive the CME certificate. To obtain credits, participants must be present every day of the activity.